Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

921 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial.
den Dekker WK, Van Mieghem NM, Bennett J, Sabate M, Esposito G, van Bommel RJ, Daemen J, Vrolix M, Cummins PA, Lenzen MJ, Boersma E, Zijlstra F, Diletti R; BioVasc Trial Investigators. den Dekker WK, et al. Among authors: zijlstra f. Am Heart J. 2020 Sep;227:111-117. doi: 10.1016/j.ahj.2020.06.006. Epub 2020 Jun 15. Am Heart J. 2020. PMID: 32739537 Free article.
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction.
Zijlstra F, Patel A, Jones M, Grines CL, Ellis S, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, Ribichini F, Granger C, Akhras F, Weaver WD, Simes RJ. Zijlstra F, et al. Eur Heart J. 2002 Apr;23(7):550-7. doi: 10.1053/euhj.2001.2901. Eur Heart J. 2002. PMID: 11922645
Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.
van 't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, Petronio S, Marcel Gosselink AT, Jap W, Hollak F, Hoorntje JC, Suryapranata H, Dambrink JH, Zijlstra F; On-TIME study group. van 't Hof AW, et al. Among authors: zijlstra f. Eur Heart J. 2004 May;25(10):837-46. doi: 10.1016/j.ehj.2004.04.003. Eur Heart J. 2004. PMID: 15140531 Clinical Trial.
Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial--a prospective, multicenter, randomized trial.
Hirsch A, Nijveldt R, van der Vleuten PA, Biemond BJ, Doevendans PA, van Rossum AC, Tijssen JG, Zijlstra F, Piek JJ; HEBE investigators. Hirsch A, et al. Among authors: zijlstra f. Am Heart J. 2006 Sep;152(3):434-41. doi: 10.1016/j.ahj.2006.02.007. Am Heart J. 2006. PMID: 16923409
Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) trial.
Ottervanger JP, Ramdat Misier AR, Zijlstra F, Schalij MJ, Wever E, Jordaens LJ, Henriques JP, de Boer MJ, Robbe HW, Wellens HJ; DAPA Investigators. Ottervanger JP, et al. Among authors: zijlstra f. Am Heart J. 2006 Oct;152(4):636-40. doi: 10.1016/j.ahj.2006.06.012. Am Heart J. 2006. PMID: 16996827 Clinical Trial.
921 results